Advancing Precision Oncology with Biomarker-driven Strategies and Digital Data Solutions XTALKS on August 20, 2026 in Toronto, Canada

Precision oncology is transforming cancer care by enabling therapies to be matched to the molecular characteristics of individual patients. As biomarker-driven development expands across tumor types, sponsors face increasing challenges in identifying eligible patients, optimizing trial execution and generating the evidence needed to support regulatory, reimbursement and clinical decision-making.

This webinar will explore strategies for advancing precision oncology across the development lifecycle. Topics will include the evolving biomarker landscape and testing approaches, innovative methods for identifying and recruiting biomarker-eligible patients through decentralized and hybrid trial models and the growing role of high-quality clinical data and real-world evidence in accelerating development and demonstrating value.

The discussion will also highlight how AI-enabled data extraction, linked clinical and genomic datasets and modern evidence-generation strategies are helping sponsors gain deeper insights, improve trial efficiency and support broader adoption of precision therapies.

Register for this webinar to learn how precision oncology strategies can strengthen biomarker-driven patient identification, trial execution and evidence generation.

Who Should Attend

This webinar will appeal to:

• Biopharma and biotech professionals
• Oncology Drug Development teams
• Precision Medicine and Biomarker Strategy teams
• Clinical Development and Clinical Operations teams
• Translational Medicine and Evidence Generation professionals
• Medical Affairs and Market Access teams

What You Will Learn

Attendees will:

• Learn strategies to navigate the evolving biomarker and NGS landscape to improve patient identification, optimize trial design and accelerate precision oncology clinical development
• Discover how fit-for-purpose real-world data, AI-enabled data extraction and linked clinical and genomic datasets can strengthen evidence generation, support external comparator strategies and drive faster adoption and access to targeted therapies
• Understand the importance of high-quality clinical endpoint data to accelerate precision oncology clinical research, enhance data-driven insights and deliver greater efficiency across the drug development process

Register free of charge at https://xtalks.com/webinars/advancing-precision-oncology-with-biomarker-driven-strategies-and-digital-data-solutions/.